ArticleArchives of public health = Archives belges de sante publique2021
The global hepatitis delta virus (HDV) epidemic: what gaps to address in order to mount a public health response?
Article in Archives of public health = Archives belges de sante publique, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Prevalence, Risk Factors, and Clinical Profiles of Hepatitis D Virus in Nigeria: A Systematic Review, 2009-2024.Viruses · 2024Pooled it
- An Exploratory Evaluation of the Present Prevalence of Hepatitis D Infection in Selected Populations from Venezuela, Contrasted with Past Studies in the Country.Microorganisms · 2026Article
- Review
- Hepatitis D Virus: Enigmas and Gaps of Knowledge.Viruses · 2026Review
- Health Disparities in Hepatitis D Virus Management: A Case Series on Improving Patient Access to Bulevirtide Therapy.Gastro hep advances · 2026Article
- Article
- Proteins and peptides as antigen candidates for the immunodiagnosis of hepatitis D.Amino acids · 2025Review
- Article
- Impact of Hepatitis Delta Virus Infection on the Selection of Hepatitis B Surface Antigen Mutations.Genes · 2024Article
- Hepatitis B Virus Infection: A Mini Review.Viruses · 2024Review
- Improving Access to Anti-HDV Testing: Development and Validation of an Affordable In-House ELISA Assay.ACS omega · 2024Article
- Prevalence of HDV infections in Poland based on the experience of a single center in Silesia and literature research.Clinical and experimental hepatology · 2024Article
- The elimination of hepatitis D as a public health problem: Needs and challenges.Journal of viral hepatitis · 2024Review
- High prevalence of hepatitis delta virus among people with hepatitis B virus and HIV coinfection in Botswana.Journal of infection and public health · 2023Article
- Delta Hepatitis in the United States: Epidemiology, Testing, and Linkage to Care.Gastroenterology & hepatology · 2023Article
- Real-World Epidemiology, Treatment Patterns, and Disease Burden of Chronic Hepatitis B and HDV Co-Infection in South Korea.Infectious diseases and therapy · 2023Article
- Interferon-Free Regimens and Direct-Acting Antiviral Agents for Delta Hepatitis: Are We There Yet?Current issues in molecular biology · 2023Review
- Article
- An Insight Into the Factors Affecting the Prevalence and Natural History of Hepatitis D.Cureus · 2023Review
- Epidemiology Pattern, Prevalent Genotype Distribution, Fighting Stigma and Control Options for Hepatitis D in Bulgaria and Other European Countries.Life (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 3 countries.
Funding
Abstract
backgroundCo-infection between hepatitis B virus (HBV) and hepatitis delta virus (HDV) causes the severest chronic hepatitis and is associated with a high risk of cirrhosis and hepatocellular carcinoma (HCC). The Global Health Sector Strategy on Viral Hepatitis called for the elimination of hepatitis (- 65% mortality and - 90% incidence) by 2030. Our aims were to summarize key points of knowledge and to identify the gaps that need to be addressed to mount a public health response to HDV.
methodsWe performed a current literature review in terms of epidemiology by WHO regions, genotypes distribution and their pathogenicity, factors associated with HDV infection, mortality due to HDV infection, testing strategies and treatment.
resultsPrevalence of infection and genotypes are heterogeneous distributed, with highest prevalence in foci around the Mediterranean, in the Middle East, and in Central, Northern Asia and Eastern Asia. Persons who inject drugs (PWID) and migrants from highly endemic areas are highly affected. While antibody detection tests are available, HDV RNA tests of current infection are not standardized nor widely available. The few therapeutic options, including lofartinib, are not widely available; however several new and promising agents have entered clinical trials.
conclusionHDV infection is an poorly known cause of chronic liver disease. To mount a public health response, we need a better description of the HDV epidemic, standardized testing strategies and better treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.